The U.S. Department of Health and Human Services has approved the creation of a $91 million influenza-vaccine manufacturing facility in a joint venture between the Texas A&M University System and GlaxoSmithKline in what Chancellor John Sharp described Tuesday as “one of the most significant developments ever in the state of Texas.”
The facility will speed up the research, development and delivery of vaccines and therapeutics in cases of pandemics or other national emergencies.
The center would also supply preventive vaccine for pandemic influenza, and, once it’s up and running, will be able to supply 50 million vaccine doses within four months of receiving a strain of the flu, with initial doses ready in 12 weeks.
The facility will anchor the Center for Innovation in Advanced Development and Manufacturing in Bryan-College Station, establishing what Sharp characterized as “third coast biopharmaceuticals.” A&M is home to one of only three so-called CIADMS being created in the nation.
“It’s a game-changer not just for Texas but for folks everywhere,” Sharp said at a morning news conference with Gov. Rick Perry to announce the effort.
Perry said the center would bring more than $41 billion in in-state expenditures over the next 25 years and directly and indirectly create more than 6,800 jobs.
“More importantly there will be lives that will be saved around the world because of what is happening in the state of Texas,” said Perry.
Please Share This Information